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Supplemental Figure 1. LDK decreases viability of primary murine T-ALL cells. Four murine samples 
derived from primary T-ALL arising in Atm-/- mice and expressing high levels of PEST-truncated activated 
NOTCH1 were evaluated for growth inhibition in response to Lenaldekar (LDK). Two T-ALL cell lines are 
PTEN- (1975, 3496) and two are PTEN+ (2317, 6658).  Cells were cultured for 24 or 48 hours with Interleukin-
7 (10ng/ml) and treated with DMSO vehicle, gamma-secretase inhibitor IX (GSI-IX) or LDK (10µM). After 24 
and 48 hours, cell viability was quantified using the Cell Titre Blue Assay and expressed as percent relative to 
vehicle treatment at each time point. Experiment was repeated, one representative experiment is shown.  
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Supplemental Figure 2. LDK has selective activity against hematological malignancies and induces 
apoptosis in Jurkat cells. (A) LDK was submitted to the NCI for dose-response testing on the NCI60 panel of 
cancer cell lines.  Results are shown as the IC50 for each cell line (Red = high sensitivity/low IC50, 
Yellow/orange = medium sensitivity/medium IC50, Green = Low sensitivity/high IC50). Results are organized by 
cancer cell type with names of cell lines tested shown below their IC50 listings in the same order. (B) Annexin 
V-FITC/Propidium Iodide staining of Jurkat cells  incubated for 24 hours with DMSO, 1µM LDK, or 5µM 
Camptothecin. (C) Caspase activation demonstrated by PARP cleavage  (arrow) by 8 hours of incubation in 
1µM LDK. (D = DMSO vehicle. Vinculin loading control. Non-contiguous sections of same gel). (D)  LDK 
induction of apoptosis demonstrated by activated Caspase-3 immunostaining of Jurkat cells incubated for 16 
hrs in DMSO, 1µM  LDK, or  5µM Camptothecin. Scale bars = 2μm. For panel C, Western blots were scanned 
at room temperature using the Epson Expression 1680 scanner and software (Long Beach, CA), 16-bit 
grayscale acquisition, 600 dpi resolution. Image processing was done utilizing Adobe Photoshop software 
v9.0.2 (San Jose, CA). For panel D, fluorescence microscope used was Nikon Eclipse E600 (Melville, NY) 
using Nikon Plan Fluor 40X objective lens (Melville, NY) at room temperature. Fluorochromes used were DAPI 
and Alexa Fluor 568 goat anti-rabbit IgG secondary antibody (Invitrogen, Grand Island, NY). Camera used was 
Nuance CRI model N-MSI-420-FL (Hopkinton, MA). Image capture was done using IP Lab software version 
4.0 (Becton, Dickinson, Sparks, MD), with image presentation processed using Image J version 1.43U (NIH, 
Bethesda, MD). 
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Supplemental Figure 3. LDK-mediated reduction of AKT and mTOR phosphorylation.  (A), Dose-
response of Jurkat cells to LDK treatment for one or eight hours of incubation. Phosphorylation of AKT at 
Thr308 and mTOR at Ser2448 was assessed by Western blot. Same blot was stripped and re-probed with 
antibodies for total mTOR and AKT.  Densitometric ratios were normalized to 1 and 8 hours’ DMSO treatment. 
D = DMSO. Non-contiguous sections of same gels are shown. (B) Assessment of LDK’s ability to prevent 
serum-induced phosphorylation of serum-starved cells. CCRF-CEM T-ALL cells were serum-starved for 72 
hours then pre-treated for 30 min with DMSO, LDK (10μM) or known PI3K inhibitor Ly294002 (Ly)(10μM) 
before addition of serum to cell media. Ly blocked any re-phosphorylation of AKT. LDK did not block serum-
induced AKT re-phosphorylation and showed reduction of AKT phosphorylation first at 15 minutes post serum-
stimulation.  (C-D) Phosflow analysis of B-ALL line Ramos and pro-B cell line BaF3.  (C) Effect of Dasatinib 
(top panels) and LDK (lower panels) on SRC (Y418, left panel) and S6 (S235/236, right panels) 
phosphorylation in B-ALL line Ramos. (D) Effects of JAK Inhibitor I (top panels) and LDK (lower panels) on 
STAT3 (Ser727, left panels) and S6 (S235/236, right panels) phosphorylation in pro-B cell line BaF3. For 
panels A and B, Western blots were scanned at room temperature using the Epson Expression 1680 scanner 
and software (Long Beach, CA), 16-bit grayscale acquisition, 600 dpi resolution. Image processing and 
densitometry was done utilizing Adobe Photoshop software v9.0.2 (San Jose, CA). 
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Supplemental Figure 4. LDK does not target the AKT pathway directly, but AKT inhibition is required 
for its toxicity in Jurkat cells. (A-C) Assessment of constitutively active myristoylated, double 
phosphomimetic (T308D/S473D) AKT (myr-AKT-DD) rescue of Jurkat cells from LDK treatment. (A) Western 
blot shows expression of myr-AKT-DD, including upregulation of AKT phosphorylation target GSK-3β, and 
reduction of LDK-mediated apoptosis, as indicated by reduction in cleaved PARP. (Dox = doxycycline). (B) 
Annexin-V/PI assessment indicates a reduction of apoptosis in LDK-treated (1μM) Jurkat (myr-AKT-DD) cells 
compared to Jurkat cells, relative to vehicle-treated cells. (n=3, error bars = s.e.m.) (C) Constitutively active 
AKT increases LDK’s IC50 in Jurkat cells three-fold (double arrow) as determined by 24hr MTT viability assay. 
For panel A, Western blot was scanned at room temperature using the Epson Expression 1680 scanner and 
software (Long Beach, CA), 16-bit grayscale acquisition, 600 dpi resolution. Image processing and 
densitometry was done utilizing Adobe Photoshop software v9.0.2 (San Jose, CA). 
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Supplemental Figure 5. Time-course of LDK treatment shows progressive accumulation of cells in 
G2/M. Jurkat T-ALL cells were treated with DMSO vehicle, LDK (10µM), or Wortmannin (1µM) and cell cycle 
percentages were assessed over a 4-24 hour time period via flow cytometry. Wortmannin, a known inhibitor of 
the PI3K/AKT/mTOR pathway, shows accumulation in G0/G1 while LDK causes a progressive accumulation in 
G2/M. 
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Supplemental Figure 6. LDK treatment results in de-phosphorylation of AKT and G2/M delay in the T-
ALL cell line CCRF-CEM. (A) CCRF-CEM cells were incubated for 12 hours with no treatment, DMSO (0.1%), 
LDK (10μM), Nocodazole (3μM), or Wortmannin (1μM) then probed via Western blot for AKT phosphorylation. 
Total AKT and Vinculin = loading controls, cropped non-contiguous sections of same gel. (B) CCRF-CEM cells 
were treated for 12 hours with LDK (10μM), Wortmannin (1μM), or Nocodazole (3μM) then stained with PI and 
assessed for cell cycle status via flow cytometry. For panel A, Western blots were scanned using Epson 
Expression 1680 scanner and software, 16-bit grayscale acquisition, 600 dpi resolution. Image processing and 
densitometry was done utilizing Adobe Photoshop software v9.0.2. For panel A, Western blot was scanned at 
room temperature using the Epson Expression 1680 scanner and software (Long Beach, CA), 16-bit grayscale 
acquisition, 600 dpi resolution. Image processing and densitometry was done utilizing Adobe Photoshop 
software v9.0.2 (San Jose, CA). 
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Supplemental Figure 7. Pharmacokinetics and lack of toxicity of LDK in mice.  (A) LC/MS standard 
calibration curve for LDK detection. (B) Four groups of five male NOD-SCID mice each were injected IP b.i.d 
for two weeks with either vehicle or LDK at 16, 80, or 200mg/kg.  After the two-week course of treatment, LDK 
serum levels were determined 24 hours following last treatment by liquid chromatography followed by mass 
spectroscopy (LC/MS). One representative serum sample per treatment level is shown. (C) Plasma 
concentration-time profile (mean ± s.d,; n=3) of LDK in male Swiss Albino mice following single intravenous 
(IV) (3mg/kg) or oral (PO) (15mg/kg) administration was determined by mass spectroscopy. Single-dose half-
life of LDK was 1.7h for IV and 2h for oral administration. (D) LDK shows lack of endorgan toxicity in treated 
mice.  Kidney and liver H&E sections were taken after 2-week treatment course from vehicle- and LDK-treated 
mice (45mg/kg, oral, b.i.d.) and evaluated for endorgan toxicity.  Representative histological sections are 
shown. Scale bars = 100µm. For panel D, hematoxylin - eosin stained tissue sections were reviewed with an 
Olympus 4E/19753 microscope (Center Valley, PA) using lens of S Plan 10. The image was acquired using 
digital camera Olympus DP71 (Center Valley, PA) and was processed with DP controller. 
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Supplemental Figure 8. LDK treatment shows no significant toxicity in complete blood count, thymus, 
or spleen cell counts. LDK-treated individuals (indicated doses were given orally b.i.d.) showed no significant 
difference when compared to diluent-only treated mice (tested on day 2) in (A) peripheral blood counts, (B) 
thymus and (C) spleen differential cell counts. There was a 10% drop in the percentage of CD8 single positive 
T lymphocytes in the thymus. Total numbers of thymocytes and overall size of thymi were reduced 
approximately 50%. Each data point represents average of three mice sacrificed on the indicated time point 
and dose. Blue bars = treatment day 2, Red bars = treatment day 14, Error bars = SD. 
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Supplemental Figure 9.  Response of a collection of primary patient B-ALL samples to LDK treatment. 
(A-J) Ten primary human B-ALL cell samples were treated with LDK and the PI3K inhibitor LY294002 then 
assessed for viability via DPM measurement. Left panels – dose response of primary B-ALL sample viability 
after 48 hrs incubation in LDK. Right panels – dose response of primary B-ALL patient samples to treatment 
with LY294002.  (n values as noted, error bars = s.e.m.) Full descriptions of patient samples may be found in 
Supplemental Table 6.    
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Supplemental Table 1. Cell cycle effects of 21 candidate compounds on zebrafish embryos.  The 21 
compounds with strong effects on survival of immature zebrafish T cells were assessed for their impact on the 
cell cycle of non-lymphoid zebrafish cells between 4 and 24 hpf. (N = No, Y = Yes, None = No effect, S = S-
phase, G0/G1 = G0/G1 phase). 
 
Strong Effect 
Compound 
Number: 
Sub G1 
Peak? Delay: 
1 Y S 
2 N None 
3 (LDK) N None 
4 Y  S 
5 Y  S 
6 N  None 
7 N  None 
8 Y  S 
9 N  None 
10 N  G0/G1 
11 N  G0/G1 
12 N  G0/G1 
13 N  G0/G1 
14 N  G0/G1 & S 
15 Y  G0/G1 
16 N  G0/G1 
17 N  S 
18 N  G0/G1 
19 Y  G0/G1 
20 Y  G0/G1 
21 N  G0/G1 
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Supplemental Table 2. LDK has minimal impact on zebrafish embryonic and larval development.  
Larvae were inspected after 48 hrs treatment by light microscopy and health and development was assessed. 
Toxicity was ranked: Grade I – no effect, Grade II – mild edema, Grade III – sick, impaired behavior, Grade IV 
– lethal. (hpf = hours post-fertilization). 
 
Age at beginning 
of treatment 
Toxicity Ranking after 48 hrs of treatment 
Untreated Vehicle   LDK 10μM 
24 hpf Grade I-   96% 
Grade II-  None 
Grade III- None 
Grade IV- 4% 
Grade I-   66% 
Grade II-  None 
Grade III- None 
Grade IV- 34% 
Grade I-   35% 
Grade II-  35% 
Grade III- None 
Grade IV- 30% 
48 hpf Grade I-   96% 
Grade II-  None 
Grade III- None 
Grade IV- 4% 
Grade I-   88% 
Grade II-  None 
Grade III- None 
Grade IV-12% 
Grade I-    ~74% 
Grade II-   ~10% 
Grade III-  None 
Grade IV- 16% 
72 hpf Grade I-   97% 
Grade II-  None 
Grade III- None 
Grade IV- 3% 
Grade I-   93% 
Grade II-  None 
Grade III- None 
Grade IV- 7% 
Grade I-   ~80% 
Grade II-  ~10% 
Grade III- None 
Grade IV- 10% 
96 hpf Grade I-   97% 
Grade II-  None 
Grade III- None 
Grade IV- 3% 
Grade I-   90% 
Grade II-  None 
Grade III- None 
Grade IV- 10% 
Grade I-    ~73% 
Grade II-   ~10% 
Grade III-  None 
Grade IV- 17% 
120 hpf Grade I-   90% 
Grade II-  None 
Grade III- None 
Grade IV- 10% 
Grade I-   84% 
Grade II-  None 
Grade III- None 
Grade IV- 16% 
Grade I-    78% 
Grade II-   None 
Grade III-  8% 
Grade IV- 14% 
 
17 
 
Supplemental Table 3.  LDK is not a general kinase inhibitor. 33 kinases/phosphatases were selected for 
assessment of LDK activity in vitro.  Four increasing concentrations of LDK were used per kinase or 
phosphatase and change in activity level was measured.  The non-selective kinase inhibitor staurosporine was 
used as a positive control. Experiments conducted by SignalChem (Richmond, BC). 
 
 Target  
%Activity change 
(0.2 µM LDK) 
%Activity change 
(1 µM LDK) 
%Activity change 
(5 µM LDK) 
%Activity change 
(25 µM LDK) 
%Activity change 
(1 µM Staurosporine) 
 AKT1 -6 -2 -9 -20 -93 
 AKT2 0 -7 -14 -22 -93 
 AKT3  0 6 -1 -1 -85 
 AMPK(A1/B1/G1) -3 2 1 -1 -93 
 PTPRC (CD45) 1 2 -3 -6 1 
 c-KIT 0 1 -3 -7 -95 
 CAMK1 2 4 3 -1 -89 
 CSK -1 -5 -6 -13 -53 
 ERK1 1 -1 -3 -1 -32 
 FAK 2 3 5 4 -97 
 FYN A -3 -1 -4 -7 -92 
 GSK-3β -6 -8 -15 -17 -91 
 HCK -2 -6 -10 -14 -99 
 ITK -2 3 2 1 -100 
 JNK1 -4 -3 0 2 -40 
 JNK2 0 -2 -6 0 -32 
 LCK 3 3 -2 -4 -76 
 LYN A 0 0 -5 -10 -96 
 MEK1 0 0 -11 -16 -72 
 p38α 3 1 1 -7 -6 
 p38δ 1 1 0 0 -9 
 PI3K (p110α/p85α) -1 -3 -8 -9 -16 
 PI3K (p110β/p85α) 6 0 -4 -5 -26 
 PDK1 -3 -5 -2 -4 -86 
 PIM1 -5 -9 -18 -25 -100 
 PKCγ -1 -3 -6 -8 -93 
 PKCθ -3 -7 -3 -5 -99 
 PKCζ 1 1 1 -8 -68 
 SRC -1 -11 -15 -18 -87 
 SYK -1 -1 -6 -11 -95 
 TEC -2 -8 -7 -11 -92 
 YES1 -4 -4 -7 -28 -98 
 ZAP70 1 2 -2 -5 -99 
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Supplemental Table 4. LDK treatment results in G2/M arrest for sensitive T-ALL and B-ALL cell lines.  
T-ALL (Jurkat, CCRF-CEM) and B-ALL (697, Nalm-6, and RS4;11) cell lines were treated with either DMSO 
vehicle only, LDK, or Wortmannin.  All LDK-sensitive cell lines (Jurkat, CCRF-CEM, 697, Nalm-6) show G2/M 
accumulation upon treatment with LDK, whereas the LDK-resistant B-ALL cell line RS4;11 shows accumulation 
in G0/G1 upon treatment with LDK.  Wortmannin, a known inhibitor of the PI3K pathway, causes G0/G1 
accumulation in all lines tested with the exception of 697. Cell cycle percentages shown are average of three 
separate experiments ± s.d.  
 
Cell Line Treatment 
% Cells / Phase 
G0 / G1 S G2 / M 
Jurkat 
 
DMSO (0.1%) 47 ± 2 38 ± 1 15 ± 1 
 
LDK 10 µM 44 ± 3 28 ± 2 28 ± 2 
 
Wortmannin 1 µM 59 ± 2 27 ± 1 15 ± 2 
CCRF-CEM 
 
DMSO (0.1%) 39 ± 2 41 ± 2 20 ± 1 
 
LDK 10 µM 42 ± 2 33 ± 2 25 ± 0 
 
Wortmannin 1 µM 45 ± 4 36 ± 4 20 ± 0 
697 
 
DMSO (0.1%) 42 ± 3 35 ± 6 23 ± 3 
 
LDK 10 µM 32 ± 4 30 ± 11 39 ± 7 
 
Wortmannin 1 µM 42 ± 6 34 ± 7 24 ± 1 
Nalm-6 
 
DMSO (0.1%) 44 ± 2 45 ± 2 11 ± 1 
 
LDK 10 µM 44 ± 4 32 ± 1 24 ± 6 
 
Wortmannin 1 µM 56 ± 2 33 ± 2 10 ± 1 
RS4;11 
 
DMSO (0.1%) 49 ± 1 43 ± 2 8 ± 4 
 
LDK 10 µM 65 ± 3 27 ± 3 9 ± 1 
 
Wortmannin 1 µM 67 ± 5 27 ± 5 6 ± 1 
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Supplemental Table 5. Characteristics of primary BCR-ABL translocated B-ALL and CML patient 
samples and growth inhibition by LDK treatment.   
 
Sample ID 
(Type) 
Gender / 
Age Cytogenetics 
BCR-
ABL1 
BCR-ABL1 
mutation 
Cell Isolation / 
Clinical Course 
MTT 
Assay 
LDK IC50 
LAX2 
 
(Ph+ B-ALL) m/38 t(9;22)(q34;q11) p210 T315I 
Relapse (on 
 
Imatinib) 0.814 µM 
SFO2 
 
(Ph+ B-ALL) m/7 m/8 t(9;22)(q34;q11) p210 unmutated 
Diagnosis and 
 
Relapse (on 
 
Nilotinib) 0.762 µM 
BLQ5 
 
(Ph+ B-ALL) f 
FISH der(9), 
 
der(22) p190 T315I 
Relapse (on 
 
Imatinib) 0.939 µM 
 
TXL3 
 
(Ph+ B-ALL) N/A t(9;22)(q34;q11) p210 unmutated Diagnosis 0.888 µM 
ICN1 
 
(Ph+ B-ALL) N/A t(9;22)(q34;q11) p210 unmutated Diagnosis 0.795 µM 
 
Sample 
ID 
Leukemia 
Type 
Age at 
Diagnosis Gender Cytogenetics 
Source 
(BM or 
PB) 
BCR-ABL1 
mutation 
Prognosis/ 
Outcome 
10-003 Ph+ CML 43 M BCR-ABL PB Unmutated Alive 
11-007 Ph+ CML N/A F 
BCR-ABL 
(T315I) PB (T315I) Alive 
11-008 
Ph+ B-
ALL 62 M 
Complex 
Karyotype PB 
Complex 
Karyotype Alive 
11-018 
Ph+ B-
ALL N/A M BCR-ABL PB Unmutated Alive 
11-032 
Ph+ B-
ALL 62 M 
Complex 
Karyotype PB 
Complex 
Karyotype Alive 
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Supplemental Table 6. Characteristics of primary B-ALL patient samples and LDK-mediated inhibition 
of proliferation.  
 
Sample 
ID 
Age at 
Diagnosis Gender 
PB WBC 
Count (109) 
Source 
(BM or PB) Cytogenetics 
Prognosis / 
Outcome 
80047 55 Female 129 PB MLL rearrangent Alive 
45 67 Female 79 PB BCR-ABL Deceased 
80558 46 Female 22 PB BCR-ABL (p190) Alive 
724622 46 Male 135 PB BCR-ABL Deceased 
80077 21 Male 5 BM t(2;3) Deceased 
534061 44 Male N/A N/A N/A Deceased 
533943 25 Male N/A N/A N/A Deceased 
544226 57 Female N/A N/A N/A Deceased 
662 30 Male 89 PB xy del. 17 (p11.2) Deceased 
1012 16 Male 9 BM Normal Alive 
 
Sample 
ID 
LDK Ly294002 
1 µM 3 µM 10 µM 1 µM 3 µM 10 µM 
80047 16 ± 4 27 ± 6 23 ± 5 10 ± 6 N/A 65 ± 1 
45 24 ± 4 32 ± 2 63 ± 3 13 ± 7 43 ± 3 63 ± 5 
80558 35 ± 2 34 ±6 81 ± 3 19 ± 3 21 ± 1 44 ± 0 
724622 63 ± 1 64 ± 1 75 ± 1 24 ± 2 44 ± 4 81 ± 1 
80077 22 ± 3 2 ± 4 85 ± 2 13 ± 6 35 ± 3 81 ± 1 
534061 54 ± 2 67 ± 1 79 ± 1 N/A N/A N/A 
533943 25 ± 4 -8 ± 11 -78 ± 15 16 ± 3 20 ± 8 43 ±1 
544226 58 ± 3 65 ± 3 75 ± 2 30 ± 4 48 ± 4 79 ± 2 
662 42 ± 2 22 ± 9 -4 ± 8 25 ± 4 50 ± 4 76 ± 2 
1012 2 ± 9 N/A 84 ± 2 N/A N/A N/A 
Percent inhibition +/- s.e.m., normalized  to vehicle control 
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Supplemental Methods 
 
Cell lines and cell culture 
 
All cells were cultured in media containing 100U/mL Penicillin (Invitrogen) and 100µg/mL Streptomycin 
(Invitrogen) and incubated at 37°C and 5% CO2. T-ALL cell lines Jurkat, MOLT-3, HPB-ALL and CCRF-CEM 
were grown in RPMI 1640 media (Invitrogen) supplemented with 10% FBS (Atlanta Biologicals, Lawrenceville, 
GA). CCRF-CEM-Luc was grown in the presence of 0.3 mg/mL Geneticin.  The T-ALL cell lines HPB-ALL and 
CCRF-CEM-Luc were a kind gift of Adolfo Ferrando (Columbia University, New York, NY).  B-ALL cell lines 
697, Nalm-6, Kasumi-2, and RS4;11 were grown in RPMI 1640 media supplemented with 20% FBS.  RS4;11 
was a kind gift of Andrew Kung (DFCI, Boston, MA).  U138 (glioblastoma), Lox (melanoma), and SW480 (colon 
cancer) were grown in DMEM media supplemented with 10% FBS and 2mM L-glutamine.  All cell lines were 
cultured in media containing 100U/mL Penicillin (Invitrogen) and 100µg/mL Streptomycin (Invitrogen) and 
incubated at 37°C and 5% CO2. 
 
In vitro drug treatment  
 
Lenaldekar was initially obtained from the ChemBridge DIVERSet® library (ChemBridge, San Diego, CA).  
Subsequently LDK was manufactured by the University of Utah Chemistry Department (M.S., K.B.) using the 
following components: hydroxyquinoline (Sigma-Aldrich), hydrazine hydrate (Sigma-Aldrich), and indole-3-
carboxaldehyde (Sigma-Aldrich).  Camptothecin, Nocodazole, imatinib, γ-secretase inhibitor IX, 
dexamethasone, LY294002, UCN-01 and  Wortmannin were obtained from Sigma-Aldrich.  AKT Inhibitor IV 
and Doxorubicin were obtained from Calbiochem. Taxol was obtained from VWR (Radnor, PA). Drugs were 
dissolved in 100% DMSO then diluted for experimentation such that the final concentration of DMSO did not 
exceed 0.1%.  
 
MTT assays 
 
Cells were plated in 96-well plates at a density of 25,000 cells per well for RS4;11, 100,000 cells per well for 
peripheral blood T-cells, and 50,000 cells per well for all other cell types.  Cells were exposed to treatment 
conditions for the indicated durations at 37°C and 5% CO2 then incubated with thiazolyl blue tetrazolium 
bromide (MTT) reagent (Sigma-Aldrich Corp., St. Louis, MO) for an additional 3 hours.  Each well was washed 
one time with HBSS then DMSO was added to dissolve the formazan crystals.  Absorbance values were then 
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measured at 570nm with a Bio-Rad microplate spectrophotometer (Bio-Rad, Hercules, CA).  The absorbance 
values were background subtracted and normalized to vehicle (DMSO) treated values.  Concentration 
response curves were generated using non-linear regression with the GraphPad Prism® software package 
(GraphPad Software, Inc., La Jolla, CA) to generate IC50 values. 
 
Viability of Atm-/- mouse primary T-ALL cell lines 
 
A detailed characterization of these lines will be published elsewhere.  Briefly, IL-7-dependent cell lines were 
established from primary T-ALLs arising in Atm-/- mice. Expression of PTEN and activated NOTCH1 in the 
primary T-ALLs was evaluated by western blotting. Cells were cultured for 24 and 48 hours in IL-7 with 10μM 
γ-secretase inhibitor IX (Calbiochem, Gibbstown, NJ), LDK, or DMSO vehicle.  Cell viability was determined 
using the Cell Titre Blue® Cell Viability Assay (Promega, Madison, WI) following the manufacturer’s 
instructions. 
 
Peripheral blood T- and B-Cell isolation 
 
All cells were cultured in media containing 100U/mL Penicillin (Invitrogen) and 100µg/mL Streptomycin 
(Invitrogen) and incubated at 37°C and 5% CO2. Blood was drawn into BD Vacutainer K2 EDTA blood 
collection tubes (Becton Dickinson). Blood was diluted in an equal volume of PBS, layered over lymphocyte 
separation medium (Cellgro, Manassas, VA), and centrifuged at 1400 rpm for 20 minutes.  The mononuclear 
lymphocyte layer was transferred to a new tube, diluted with PBS, and centrifuged to pellet the lymphocytes.  
The lymphocyte pellet was diluted in 5 mL of RPMI 1640 media supplemented with 20% FBS, 100U/mL 
penicillin, and 100µg/mL streptomycin; transferred to a T25 cell culture flask, and incubated overnight at 37°C 
and 5% CO2. The following day media was removed by centrifugation and cells were suspended at a density of 
1 x 108 cells/mL.  B-cells were isolated using the EasySep CD19 positive selection kit from StemCell 
Technologies (Vancouver, BC).  Isolated B-Cells were cultured in media with 100ng/mL Interleukin-10 
(Prospec, East Brunswick, NJ) for experimental procedures.  The remaining cell suspension was then subject 
to T-Cell isolation using the EasySep CD3 positive selection kit from StemCell Technologies.  Isolated T-Cells 
were cultured in media with 30IU/mL Interleukin-2 (Hoffman-La Roche Inc., Nutley, NJ) for subsequent 
experimental procedures. 
 
In vitro apoptosis assay 
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Jurkat cells were treated with DMSO vehicle (0.1%), 1µM LDK or 5µM Camptothecin for 24 hours then stained 
with propidium iodide and Annexin V-FITC (BD Pharmingen) according to the manufacturer’s instructions. 
Apoptosis was determined via flow cytometry in a FACScan analyzer (Becton Dickinson). 
 
Western blot analysis 
 
Cells were treated with the indicated compounds, pelleted and washed with cold PBS. Protein was extracted 
via 10 min incubation on ice in cell lysis buffer (25mM TRIS pH 7.4, 150mM NaCl, 1mM CaCl2, 1% Triton X-
100) with phosphatase (Sigma-Aldrich) and protease (Sigma-Aldrich) inhibitors.  Protein density was 
determined via Bio-Rad Protein assay.  Proteins were separated via gel electrophoresis on SDS-PAGE gels 
(Invitrogen).  Protein was then transferred to PVDF membrane and the membrane incubated in milk block (5% 
non-fat dry milk powder in 1% PBS-T) for either 1 hour at room temperature or overnight at 4°C. Membranes 
were then incubated for either 1-3 hours at room temperature or over night at 4°C in primary antibody diluted in 
primary antibody dilution buffer (5% BSA, 0.1% Tween 20 and 0.01% NaN3 in PBS, filtered at 0.45μm).  
Primary antibodies purchased from Cell Signaling included PARP, AKT, p-AKT(Ser473), p-AKT(Thr308), 
mTOR, p-mTOR(Ser2448), PTEN, p70S6K, p-p70S6K(Thr389), Cyclin A and Cyclin B1. Phospho-Histone H3 
antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Actin primary antibody was 
purchased from ImmunO MP Biomedicals (Solon, OH).  Vinculin antibody was purchased from Sigma.  All 
primary antibodies were utilized at a 1:1,000 dilution ratio in primary antibody dilution buffer with the exceptions 
of vinculin (1:5,000) and p-AKT(Ser473) (1:2,000). Blots were then washed 3x for 10 min each in PBS-T and 
incubated in secondary antibody.  Secondary antibodies used were sheep-anti-mouse (Amersham, 
Piscataway, NJ) and donkey-anti rabbit (Amersham) at a 1:10,000 dilution in milk block for 1 hour at room 
temperature.  Blots were then washed again 3x for 10 min each in PBS-T.  Chemiluminescence was assessed 
using WESTERN LIGHTNING-Plus-ECL horseradish peroxidase (PerkinElmer, Waltham, MA) and exposed to 
Amersham Hyperfilm ECL film (GE Healthcare, Piscataway, NJ). Densitometry was done utilizing Adobe 
Photoshop CS2 v9.0.2 histogram feature.  
 
Immunocytochemistry   
 
Jurkat cells were treated with test compounds or DMSO vehicle for 16 hours at 37° C.  Samples were fixed in 
4% paraformaldehyde for 20 minutes and then permeabilized with 0.1% Triton X-100 for 15 minutes.  Samples 
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were then washed and resuspended in PBS/1%BSA and spun onto glass slides with a Shandon Cytospin3 
cytocentrifuge (Thermo Scientific, Asheville, NC) at 600 rpm for 5 minutes.  Slides were blocked in TBS buffer 
with 0.1% Triton X-100, 2% BSA, and 0.1% azide for 10 minutes, then incubated with active caspase-3 rabbit 
polyclonal antibody (BD Bioscience, San Jose, CA) diluted 1:200 in PBS/1%BSA for 60 minutes at room 
temperature.  Slides were washed 3 times, then incubated with Alexa Fluor 568 goat anti-rabbit IgG secondary 
antibody (Invitrogen) diluted 1:1000 in PBS/1%BSA for 60 minutes at room temperature.  Slides were washed 
3 times then incubated with 50nM DAPI (Sigma) for 3 minutes.  Slides were washed, allowed to dry briefly, and 
a coverslip was mounted to each slide with a drop of Prolong Gold (Invitrogen) and allowed to dry overnight.  
Slides were then imaged on a Nikon eclipse E600 fluorescence microscope (Nikon Instruments Inc., Melville, 
NY). 
 
Statistical analyses 
 
For mouse xenograft results, p-values were calculated utilizing Wilcoxon rank sum test (non-parametric test) 
due to non-normal distribution of tumor emittence data.  Alpha level = 0.05, two-tailed test.  For each p-value, 
comparison of interest was vehicle control vs. LDK-treated emittance for the pertinent experimental timepoint. 
 
Phosflow experiments 
 
Phosflow staining of Ramos B cell lymphoma and IL-3-dependent BaF3 pro-B cell lines was performed using 
BD Phosflow antibodies (BD BioSciences, San Diego, CA), BD Fix Buffer I and BD Perm Buffer III according to 
the manufacturer’s protocol. Non-viable cells were excluded based on staining with Fixable Blue (Invitrogen, 
Carlsbad, CA) used according to the manufacturer’s protocol. Dasatinib was purchased from Toronto 
Research Chemicals (Toronto, ON Canada) and JAK Inhibitor I was purchased from Calbiochem. 
Immunofluorescence was analyzed using a SORP LSRII (BD Biosciences) equipped with 4 lasers emitting at 
488nm (100mW), 633nm (20mW), 405nm (25mW) and 355nM (25mW). 
 
AKT double phosphomimetic mutagenesis.  
The pTRE2-hyg vector (Clontech) containing myristoylated AKT was a kind gift of Steven Grant, MD (Virginia 
Commonwealth University) and has been described previously (Supplemental Reference 1).  AKT double 
phosphomimetic mutations (T308D/S473D) were introduced into the myr-AKT construct using Agilent 
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Technologies QuikChange Lightning™ Multi-Site Diected Mutagenesis Kit (Cat# 210515-5) according to the 
manufacturer’s instructions.  For AKT(T308D) mutagenesis, the primer used was 5’-
GGTGCCACTATGAAGGACTTCTGCGGAAC GCCG-3’. For AKT(S473D) mutagenesis, the primer used was 
5’-ACTTCCCCCAGTTCGACTACTCA GCCAGTGG-3’ (mutated bases shown in bold font). Sequence-verified 
myristoylated AKT(T308D/S473D) constructs (myr-AKT-DD) were introduced into Jurkat cells via nucleofection 
using the LONZA Amaxa™ Cell Line Nucleofector Kit V (Cat# VCA-1003) according to the manufacturer’s 
instructions for optimized delivery to Jurkat Clone E6.1 cells. Nucleofected cells were then selected in 
0.5mg/mL hygromycin for two weeks. The pLVX-Tet-On (Clontech) tetracycline-response control vector was 
utilized to generate lentivirus via standard methods in HEK293 cells. Jurkat cells previously selected in 
hygromycin for stable expression of the myr-AKT-DD construct were transduced with pLVX-Tet-On carrying 
lentivirus then selected in dual 0.5mg/mL neomycin/hygromycin for two weeks before testing for myr-AKT-DD 
transgene expression and LDK resistance. 
 
In vitro kinase assay 
 
In vitro kinase assay was performed by SignalChem, Inc. (Richmond, BC).  LDK was tested in triplicate against 
33 purified kinase/phosphatases (See Supplemental Table 3) and their peptide targets, utilizing four increasing 
LDK concentrations of 0.2µM, 1µM, 5µM, and 25µM. Read-out for kinase assay was incorporation of 33P. 
Read-out for phosphatase assay was absorbance at 410nm utilizing pNPP as substrate.  The general 
kinase/phosphatase inhibitor staurosporine was used at 1µM as positive control. Further specific in vitro kinase 
assay methods may be found online at www.signalchem.com.  An additional 451 kinases were tested by 
KINOMEScan (San Diego, CA) at 1µM LDK.  Further information regarding KINOMEScan methods may be 
found online at www.kinomescan.com. 
 
Cell cycle analysis  
 
Cell cultures were suspended in media at a density of 500,000 cells/mL and exposed to the treatment 
conditions in 6-well cell culture plates for the indicated time at 37°C.  Cells were harvested, washed with PBS, 
and fixed with 70% ethanol at 4°C for a minimum of 2 hours.  Fixed cells were washed with PBS and stained 
with 10μg/mL propidium iodide (Invitrogen) with 1mg/mL RNase A (Invitrogen) for 30 minutes at 37°C, then 
placed on ice prior to analysis. DNA staining and cell cycle analysis was then done by flow cytometry.  
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LDK mouse blood serum level determination 
 
Initial pharmacokinetic analysis was performed by Advinus, Inc. (Bangalore, India) (See Supplemental Fig. 7).  
Briefly, male Swiss Albino mice were divided into two groups and given a single dose bolus of LDK either 
intravenously at 3mg/kg via tail vein injection or orally at 15 mg/kg via gavage feeding.  LDK solution was 
prepared by dissolving it in an aqueous diluent consisting of 5% N,N-dimethylacetamide, 5% Cremophor-EL, 
and 5% dextrose at pH 6.0 and filter-sterilizing it through a 0.22μm filter syringe.  LDK for IV administration was 
resuspended in diluent to a concentration of 0.5 mg/mL with an injection volume of 6 mL/kg. LDK for oral 
administration was resuspended in the same diluent to a concentration of 1.5 mg/mL with an administration 
volume of 10 mL/kg.  Following LDK administration, three treated mice were assessed per time point per 
treatment for blood serum LDK levels via retro-orbital blood draw and serum separation followed by LC-MS 
analysis.  Pharmacokinetic parameters were calculated using non-compartmental analysis tool of WinNonlin 
Enterprise (Version 5.1.1) software (Pharsight Inc, Sunnyvale, CA). For LDK blood serum level determination 
following maximum tolerated dose study (See Supplemental Fig. 7), male NOD-SCID mice were divided into 
four groups of five mice each and injected IP b.i.d. for two weeks with either diluent only or 16, 80, or 200 
mg/kg LDK, respectively.  24 hours following the last injection, mice were exsanguinated and serum was 
separated for LC/MS analysis of LDK serum levels by J.C. 
 
Liquid chromatography-mass spectrometry (LC-MS)  
 
For LC-MS analysis of LDK, an integrated system consisting of two Shimadzu LC-10AD VP pumps, a CBM-
20A controller and an API 365 triple quadrupole mass spectrometer modified with an Ionics EP10+ source was 
employed. Parameter optimization was performed by direct infusion of LDK dissolved in acetonitrile. The 
parent mass of 287.2 m/z and the daughter mass of 144.2 was determined to be optimal for quantification in 
the positive mode.  An HPLC method was developed using a HyperClone 100 x 4.6 mm 3 ODS column 
(Phenomenex, Torrance, CA).  Solvents employed for this were MS grade acetonitrile and 5 mM ammonium 
formate buffer, pH 3.2. Flow rate was 0.5 mL/min.  The column was held initially at 10% acetonitrile for 1 
minute followed by a linear gradient to 90% acetonitrile over 4 minutes.  This concentration was held for 2 
additional minutes followed by a downward ramp back down to 10% acetonitrile.  The column was re-
equilibrated for 4 minutes at 10% acetonitrile.  Using this method the retention time for LDK was determined to 
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be 6.3 minutes.  A calibration curve was generated with the lower limit of detection (LOD) determined to be 
6.25 ng/mL.  A liquid-liquid extraction method was developed and optimized for the analysis of LDK in serum 
and tissue by spiking bovine serum with LDK and extracting twice with equal parts of toluene. 
 
Isolation and analysis of mouse tissues  
 
Groups of 3 animals per dose of drug were evaluated every 3 to 4 days by peripheral blood analysis and for 
cellularity and immunophenotype of cells in spleen and thymus. Peripheral blood was collected from the retro-
orbital sinus and subjected to differential cell counting using a Serono System 9010+CP hematology counter 
(Serono Diagnostics, Allentown, PA). Spleen and thymus tissue was dissociated in Hank’s Balanced Salt 
Solution (HBSS) containing 5% newborn calf serum, red blood cells were eliminated by ammonium chloride 
lysis. Cell counts were determined as above and 2 x 106 cells were incubated with labeled monoclonal 
antibodies to detect CD4, CD8, and CD19. Flow cytometry was performed using a FACScan flow cytometer 
(BD Biosciences, San Jose, CA; modified by Cytek Development, Fremont, CA). Four-micron thick sections 
were cut and stained with hematoxylin and eosin. Mouse tissues were examined for evidence of necrosis or 
toxicity by A.A.   
 
B-ALL cell culture and treatment 
 
Primary human B-ALL samples were cultured in StemSpan (Stem Cell Technologies, Vancouver, BC) serum-
free expansion medium for hematopoietic cells supplemented with 1 mM L-glutamine, 10mM Hepes, 0.1mM 
non-essential amino acids, and 1mM sodium pyruvate. Cells were treated with test compounds or vehicle for 
72 hours.  During the last 16 hours of culture the cells were pulsed with [3H]-thymidine.  At the end of the 
incubation period the cells were harvested and run on a scintillation counter to measure dpm as a readout of 
cell proliferation. 
  
CML clonogenic and viability analysis  
 
Methylcellulose clonogenic assays were carried out by plating 103 CML-CPCD34+ or Ph+ALL MNCs 0.9% 
MethoCult (Stem Cell Technologies) in the presence of the cytokine cocktails described above, and either 
untreated or treated with LDK (0.1, 1.0, 3.0, 10.0μM) or imatinib (2.5μM). Colonies (>100μm) from primary cells 
were scored on day 12. Trypan blue exclusion was used to assess cell viability. 
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CD34+ hematopoetic stem/progenitor cell isolation and assay for LDK sensitivity  
 
Umbilical cord blood samples were received within 48 hours of harvest.  Samples were centrifuged and the 
pellet was suspended in red blood cell (RBC) lysis buffer and incubated on ice for 5 minutes.  Cells were then 
pelleted, washed with PBS/2 mM EDTA, layered over cold Ficoll, and centrifuged at 1,800 RPM for 30 minutes.  
Mononuclear cells were then collected and washed in PBS/2 mM EDTA.  CD34+ separation was then 
performed with an AutoMACS Pro separator and CD34 Multisort MicroBeads from Miltenyi Biotec (Auburn, 
CA).  The CD34+ cells were then cultured in RPMI supplemented with 10% FBS, StemSpan® CC100 cytokine 
cocktail (STEMCELL Technologies, Vancouver, BC), and 50 ng/mL recombinant human thrombopoietin 
(Invitrogen, Carlsbad, CA).  Cells were immediately plated in 96-well plates, treated with compound or vehicle, 
and incubated for 48 hours.  After incubation the cell viability was determined by MTT analysis. 
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